Posted on

Incretin-based medications transforming treatment of type 2 diabetes and obesity

Loading

By Michael Monostra

The development of incretin-based molecules has led to therapies that can induce greater reductions in HbA1c and body weight for people with type 2 diabetes and obesity than other classes of medication, according to a speaker.

At the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, Richard E. Pratley, MD, a Healio | Endocrine Today Co-editor and the Samuel E. Crockett chair in diabetes research and medical director at AdventHealth Diabetes Institute, discussed the history of incretin-based therapies and continuing advances today. Read the article in Healio.

Loading
Posted on

About 40% of patients with type 2 diabetes discontinue second-line medication

Loading

By Andrew (Drew) Rhoades

Almost 40% of patients with type 2 diabetes stopped taking their second-line medication within 1 year, putting them at risk for future hospitalization related to diabetes, according to researchers.

Previous research has found alarming antidiabetic medication (ADM) usage trends because most adults with type 2 diabetes are eligible for GLP-1 receptor agonists and SGLT2 inhibitors but few use them. Read the article in Healio.

Loading
Posted on

Walking faster may reduce risk for developing type 2 diabetes

Loading

By Michael Monostra

Walking at a faster speed may decrease the risk for developing type 2 diabetes, though more studies are needed to confirm the association, according to findings from a systematic review and meta-analysis.

“Currently, there is no specific instruction for gait speed in current guidelines,” Ahmad Jayedi, PhD, a research assistant at the Social Determinants of Health Research Center at Semnan University of Medical Sciences in Iran, told Healio. Read the article in Healio.

Loading
Posted on

Type 2 diabetes associated with higher risk for colorectal cancer

Loading

By Matthew Shinkle

Risk for developing colorectal cancer increased by 47% among individuals with type 2 diabetes, according to results from a cohort study designed to over-represent African Americans and low-income patients.

The increased risk for colorectal cancer (CRC) may be reduced by colonoscopy screening among individuals with diabetes, according to researchers. Read the complete article in Healio.

Loading
Posted on

Higher salt intake associated with increased risk for type 2 diabetes

Loading

By Andrew Rhoades

Greater salt consumption was linked to an increased risk for type 2 diabetes, according to a study published in Mayo Clinic Proceedings.

“We already know that limiting salt can reduce the risk for cardiovascular diseases and hypertension, but this study shows for the first time that taking the saltshaker off the table can help prevent type 2 diabetes as well,” Lu Qi, MD, PhD, a professor at the Tulane University School of Public Health and Tropical Medicine, said in a press release.
Read the full article in Healio.

Loading
Posted on

Cost of diabetes care in US rises to $412.9 billion in 2022

Loading

By Michael Monostra

The total annual cost of caring for Americans with diabetes in 2022 was an estimated $412.9 billion, and one in four total health care dollars in the U.S. went toward diabetes care, according to a report.

The American Diabetes Association published its Economic Costs of Diabetes in the U.S. in 2022 report in Diabetes Care to assess the financial burden for people living with diabetes.
Read the full article in Healio.

Loading
Posted on

Diabetic Eye Screening: Reducing Frequency May Raise Retinal Risks

Loading

— Switching from annual to biennial exams would delay diabetic retinopathy diagnoses, study shows

By Randy Dotinga

Reducing the frequency of eye screening in patients with diabetes from annually to every other year would delay detection of sight-threatening diabetic retinopathy (STDR) and proliferative diabetic retinopathy (PDR), according to real-world data from a multi-ethnic population-based retrospective cohort study.

Among over 82,000 patients with diabetes in the London area, diagnosis of STDR would have been delayed by 1 year in 56.3% of patients, while diagnosis of PDR would have been delayed in 43.6%, reported Christopher Owen, PhD, of St. George’s University of London, and colleagues in the British Journal of Ophthalmology. Read the full article in MedPage Today.

Loading
Posted on

Early diagnosis, treatment intensification essential to improve diabetes outcomes

Loading

By Regina Schaffer

BOSTON — Interventions that prevent or delay the onset of type 2 diabetes are critically important, and early diagnosis and treatment intensification can improve outcomes and increase lifespan, according to a speaker.

Despite the development of several new classes of diabetes medications and devices and advances in understanding of the importance of glucose control, only about half of people with type 2 diabetes are achieving a target HbA1c of less than 7%, Juan P. Frias, MD, medical director and principal investigator at Velocity Clinical Research in Los Angeles, said during a presentation at the Cardiometabolic Health Congress. Read the complete article in Healio.

Loading
Posted on

Islet transplantation may reduce failure risk, boost life expectancy in patients with type 1 diabetes

Loading

By Shawn M. Carter

Pancreatic islet transplantation may reduce transplant failure risk and boost long-term survival vs. insulin alone in kidney transplant recipients with type 1 diabetes, new data show.

“Although islet transplantation has previously been shown to improve glycemic control compared with conventional insulin therapy, little was known about its long-term impact until now,” lead researcher Mehdi Maanaoui, MD, a nephrologist at the Centre Hospitalier Régional Universitaire de Lille, in France, said in a press release. Read more in Healio.

Loading